Topic Listing for Medivation

Accounting Income Taxes Accounting Treatment Merger Financial Statement Presentation
Accrued Expenses Accrued Liabilities
Ackground Acknowledge Become Effective Sign Return Release Within Forty-five
Acknowledge Become Effective Sign Return Release Within Fourteen Acknowledge Become Effective Sign Return Release Within Twenty-one
Acquisition Selena Pharmaceuticals Inc Patent Rights Activities Daily Living Behavior Overall Function
Additional Eligibility Transition Matters Additional Phase Clinical Trials
Additional Trial Results Address Principal Executive Offices Zip Code
Adjustments Changes Capitalization Administration
Advanced Prostate Cancer Affiliates Associates Shall Meanings Set Forth Rule 405
After Therapy Agreement
Agreement Sell Purchase Shares Placement Agents Allocation Manufacturing Costs Joint Plan
Alzheimers Disease Alzheimers Disease Opportunity
Amended Restated 2004 Equity Incentive Award Plan Amended Restated Collaboration Agreement
Amendment Amendment Modification Termination
Amendment Termination 2004 Plan Amendment Termination Amended Restated 2004 Equity Incentive Award
Amendments Amendments Registration Statement Prospectus Supplements Free Writing Prospectuses
American Academy Neurology Annual Meeting Annual Bonus Program
Annual Incentive Bonus Program Anti-aging
Anti-aging Indications Anufacture Upply
Appointment New Independent Registered Public Accounting Firm Appointment New Principal Accountant
Appraisal Approval Amended Restated 2004 Equity Incentive Award Plan
Approval Amendment Amended Restated Certificate Incorporation Change Name Artner Xceptions Ompeting Roduct
Astellas Astellas Collaboration Agreement
Audit Committee Authorization Sale Shares Subject Terms Conditions Agreement Authorized
Authorized Shares Authorized Signatures Sign Here Completed Instructions Executed
Available Https Materialsproxyvotecom 58501n Available Information
Awards 2004 Plan Awards Amended Restated 2004 Equity Incentive Award Plan
Awards Not Transferable Background
Balance Sheet Data Base Salaries
Base Salary Base Salary Annual Incentive Bonus Program
Basic Diluted Net Loss Per Share Basis Consolidation
Basis Consolidation Business Segments Basis Presentation
Benchmarking Cash Long-term Compensation Beneficial Owner Shares Registered Name Broker Bank
Beneficial Ownership Reporting Compliance Benefits Perquisites
Board Directors Board Directors Committees
Board Directors Medivation Inc Board Directors Orion Acquisition Corp
Bonus Awards Bonus Plan
Bonuses California State Securities Law Compliance
Cash Bonuses Named Executive Officers Cash Equivalents
Cash Flow Castration-resistant Prostate Cancer
Castration-resistant Prostate Cancer Patients Cco Agreement Rohan Palekar
Ceo Agreement David Hung Certain Effects
Certain Related-person Transactions Certain Relationships Related Transactions
Certification Certification Chief Executive Officer
Certification Pursuant Rule 13a-14 15d-14 Certifications
Change Control Change Control Severance Agreements
Change Control Severance Benefits Agreement Change Vote After Submitting Proxy
Changes Capital Structure Changes Internal Control Over Financial Reporting
Changes Internal Controls Cholinesterase
Clinical Data Clinical Trial Mdv3100 Hormone-refractory Prostate Cancer
Closings Delivery Shares Funds Co-commercialize Mdv3100 Treatment Prostate Cancer
Co-promotion Products Medivation Co-promotion Terms
Code Ethics Collaboration Agreement
Collaboration Revenue Combination Therapy
Commercialization Standards Conduct Commitments Contingencies
Committed Equity Financing Facility Committed Equity Line Credit
Committees Common Stock
Common Stock Offering Common Stock Prices
Common Stock Purchase Agreement Compensation Committee
Compensation Committee Charter Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Named Executive Officers
Competition Completion Acquisition Disposition Assets
Compliance Laws Comprehensive Loss
Concentration Credit Risk Conference Call
Conference Call Begins 100 Eastern Time Today Conference Call Details
Conference Call Held Today 830 Eastern Time Conference Call Information
Conference Call Scheduled 100 Est Today- Conference Call Scheduled Today 500 Edt
Conference Call Scheduled Today 830 Eastern Time Conference Call Today 430 Eastern Time
Confirmatory Pivotal Phase Clinical Trial Connection Connection Trial Dimebon Patients Alzheimers Disease
Consent Independent Registered Public Accounting Firm Consolidated Balance Sheet
Constellation Study Consulting Agreement
Contact Study Contacts
Convertible Bridge Notes Warrants Convertible Notes Warrants
Convertible Promissory Notes Warrants Corporate
Corporate Milestones Corporate Seal
Corporate Secretary Corporate Structure
Corporate Update Covenants
Critical Accounting Policies Estimates Critical Accounting Policies Estimates Judgments
Current Report Current Reports Form 8-k
Daniel Adams Been President Chief Executive Officer Protein Dear Stockholder
Defense Collaboration Patents Delivery Funds
Delivery Shares Departure Directors Principal Officers Election Appointment
Description Business Description Merger
Description Proposed Amendment Design Horizon Study
Detailing Determination 2009 Cash Bonuses
Development Costs Development Plan Dimebon Program
Development Program Development Russia
Development Stage Development United States
Dimebon Dimebon Alzheimers Disease 2008
Dimebon Alzheimers Disease Huntingtons Dimebon Alzheimers Huntingtons Diseases
Dimebon Benefits Mild Moderate Patients 12-month Subgroup Analyses Dimebon Drug Candidate Treat Alzheimers Huntingtons Diseases
Dimebon Huntingtons Disease Trial Dimebon Latrepirdine
Dimebon Latrepirdine Alzheimers Disease Huntington Dimebon Latrepirdine Pfizer Collaboration
Dimebon Pivotal Trial Results Alzheimers Disease Dimebon Preserves Key Functions Alzheimers Patients Open-label Extension
Dimebon Trial Design Dimebon Trial Six-month Results
Dimebons Clinical Program Dimebons Novel Mechanism Action
Dimebons Purported Mechanisms Action Director Attendance Annual Meetings Stockholders
Director Compensation Director Compensation 2008
Directors Directors Not Standing Re-election
Discuss Data Dismissal Independent Registered Public Accounting Firm
Dismissal Principal Accountant Dividend Policy
Dividends Documents Incorporated Reference
Each Placement Agent Hereby Waives Right Trial Jury Effect Change Control Amended Restated 2004 Equity Incentive
Effective Expiration Date Egulatory Atters
Election Directors Eligibility
Eligibility Participation Employees
Enforcement Rights Enrollment Expanded Percent Patients-
Entry Material Definitive Agreement Epresentations Arranties Ovenants Hsr
Equity Compensation Equity Compensation Plan Information
Equity Compensation Plans Equity Incentive Plan
Equity Transactions Related Reverse Merger Erm Ermination
Escrow Account Payable Estimates
Evaluation Disclosure Controls Procedures Evelopment
Exact Name Registrant Specified Charter Exact Name Small Business Issuer Specified Charter
Except Per Share Data Exchange Act 1934
Exclusivity Execution Corporate Instruments Voting Securities
Execution Version Executive Compensation Program
Executive Compensation Summary Executive Equity Compensation
Executive Officer Hires Executive Officers
Exhibits Explanatory
Extraordinary Bonuses 2008 Fair Value Disclosures
Fair Value Financial Instruments Fair Value Recurring Basis
Fda-approved Therapeutics Purported Mechanisms Action Federal Income Tax Consequences Associated 2004 Plan
Federal Income Tax Consequences Associated Amended Restated 2004 Fees Expenses
Fees Paid Independent Registered Public Accounting Firm Financial Outlook
Financial Results Financial Results 2008 Outlook
Financial Statement Presentation Financial Statements Exhibits
Financial Statements Index Financing Activities
Find Out Results Voting Annual Meeting Fixing Record Dates
Foregoing Summary Changes Qualified Entirety Amended Restated Bylaws Foreign Currency Exchange Risk
Form 10-k Form 10-ksb
Form 10-q Form Election Purchase
Former Name Address Changed Since Last Report Forward Looking Statements
Forward-looking Statements Fractional Shares
Further Description Risks Uncertainties Found Pfizers Annual Report Further List Description Risks Uncertainties Found Pfizers Annual
General General Administrative Expense
General Indemnity General Provisions
Government Regulation Product Approvals Governmental Authority Required Divestiture
Grants Plan-based Awards Greement
Group Termination Growth Future Commercialization
Hemical Tructure Imebon Highlights Recent Accomplishments
History Hormone-refractory Prostate Cancer
Householding Proxy Materials Huntington Disease
Huntingtons Disease Icenses Xclusivity
Impairment Disposal Long-lived Assets Inancials
Inception 2003 2004 Included Best Asco Educational Program
Income Statement Data Income Taxes
Indemnification Directors Executive Officers Other Employees Agents Independence Board Directors
Independent Registered Public Accounting Firm Fees Services Index
Individual Grants Individual Group Termination
Individual Termination Information Regarding Committees Board Directors
Infringement Collaboration Patents Parties Institute Physiologically Active Compounds Partnership
Intellectual Property Intellectual Property Protection
Inter-company Transactions Interest Income
Interest Income Net Interest Other Income
Interest Other Income Expense Interest Rate Risk
Investing Activities Investor Questionnaire
Iscellaneous Ispute Esolution
Issuers Telephone Number Ist Edivation Atents
Joint Commercialization Committee Joint Development Committee
Joint Manufacturing Committee Joint Manufacturing Plan
Joint Regulatory Committee Joint Steering Committee
Keeping Records Books Account Foreign Corrupt Practices Act Licensed Territory Partner Shall Lead Regulatory Party Products
Limitations Effectiveness Controls Limits Transferability
Liquidity Capital Resources Liquidity Capital Resources Sources
Loans Officers Loss Per Common Share
Loss Per Common Shares Managements Report Internal Control Over Financial Reporting
Manufacturing Market Common Stock
Market Size Mdb Capital Group Llc Services
Mdv300 Series Compounds Mdv300 Series Prostate Cancer Program
Mdv3100 Mdv3100 Advanced Prostate Cancer Patients
Mdv3100 Astellas Collaboration Mdv3100 Castration-resistant Prostate Cancer
Mdv3100 Drug Candidate Treat Castration-resistant Prostate Cancer Mdv3100 Hormone-refractory Prostate Cancer
Mdv3100 Ongoing Phase 1-2 Trial Mdv3100 Trial Design Results Date
Mdv3100s Clinical Program Mechanism Action
Mechanism Action Moa Medivation
Medivation Announces Offering 2750000 Shares Common Stock Medivation Announces Pricing Public Offering
Medivation Appoints Chief Medical Officer Medivation Forward Looking Statement
Medivation Host Conference Call Webcast Today 830 Eastern Medivation Inc
Medivation Inc Adopts Shareholder Rights Plan Medivation Names Rohan Palekar Chief Commercial Officer
Medivation Neurology Inc Medivation Prices Registered Direct Offering
Medivation Prostate Therapeutics Inc Medivation Provides Update Huntingtons Disease Ind
Medivation Reports 2009 Financial Results Provides Corporate Update Medivation Sales Force
Meetings Meetings Board Directors
Merger Merger Financing Transactions
Metastatic Prostate Cancer-the Hormone-sensitive Castration-resistant States Miscellaneous
Name Person Filing Proxy Statement Other Registrant Name Small Business Issuer Charter
Nasdaq Global Market Ndemnification
Net Loss Per Common Share Neurodegenerative Diseases
New Plan Benefits New Product Candidates
Nitial Embers Jsc Nitial Hared Erritory Ommercialization Lan Udget
Nitial Oint Evelopment Lan Nitial Oint Evelopment Lan Utstanding Ssues
Nmda Receptor Nominating Corporate Governance Committee
Nominees Notice
Notices Nt0904 Compounds
Nt0904 Program Ntellectual Roperty
Nternational Nti Ribery Orruption Rocedure Off-balance Sheet Arrangements
Offering Officer Agreements
Officers Offices
Ollaboration Overnance Ommercialization
Ompliance Ertificate Onfidentiality
Open-label Extension Operating Activities
Option Exercises Option Exercises 2008
Option Grants Options Warrants Preferred Stock
Organization Orion Acquisition Corp
Other Agreements Financings Other Comprehensive Loss
Other Events Other Income Expense Net
Other Matters Other Non-current Liabilities
Other Securities Corporation Other Types Awards
Outstanding Equity Awards Year-end Outstanding Shares
Over-allotment Option Overview
Owned Corporation Part
Part Other Information Patients Background Memantine
Paying Proxy Solicitation Performance Graph
Performance-based Awards Pfizer Collaboration Agreement
Pfizer Disclosure Notice Information Contained Release 2009 Assumes Pfizer Forward Looking Statements Information Contained Release 2008
Pfizer Inc Pfizer Inc Collaboration Agreement
Pfizer Medivation Dimebon Collaboration Pfizer Medivation Initiate Phase Trial Dimebon Patients Huntington
Phase 1-2 Clinical Trial Subsequent Development Plans Phase Clinical Trial
Pipeline Pipeline Progress
Pivotal Clinical Trial Pivotal Study
Post-employment Obligations Potential Fast Track Status Priority New Drug Application
Potential Generation Molecules Potential Neuroprotective Activity
Potential Orphan Drug Designation Potential Payments Termination Change-in-control
Potential Payments Termination-change-in-control Power Attorney
Pre-approval Policies Pre-approval Policies Procedures
Preclinical Data Preferred Stock
Procedures Process Setting Executive Officer Performance Compensation
Product Withdrawals Recalls Program Remains Track Advance Phase Trials 2009
Prolonging Survival Pets Promotional Advertising Expense
Property Equipment Proposals
Proposed Amendments Proposed Amendments 2004 Equity Incentive Award Plan
Prosecution Patents Prostate Cancer
Prostate Cancer Mdv3100 Prostate Cancer Statistics
Provides Corporate Update Provision Income Taxes
Provisions Applicable Awards Proxy Card Properly Executed Voted Manner Directed Herein
Publicity Purchase Sale Common Stock
Purchase Shares Purpose
Quarterly Results Operations Quorum Voting
Ratification Independent Public Accountants Ratification Independent Registered Public Accounting Firm
Ratification Independent Registered Public Accounting Firm 2008 Ratification Independent Registered Public Accounting Firm 2009
Ratification Selection Independent Registered Public Accounting Firm Reasons Proposed Amendment
Receiving Materials Recent Accomplishments
Recent Accomplishments Near-term Milestones Recent Accounting Pronouncements
Recent Highlights Accomplishments Recent Sales Unregistered Securities
Recently Issued Accounting Pronouncements Recitals
Reclassification Reclassifications
Redeemable Class Unit Purchase Warrants Redeemable Preferred Stock
Refractory Prostate Cancer Trial Registered Direct Offering
Registrants Telephone Number Including Area Code Registrants Telephone Number Including Area Code 415 543-3470
Registration Common Stock Registration Rights Agreements
Regulation Disclosure Regulatory Compliance
Regulatory Costs Regulatory Responsibilities
Related-person Transactions Policy Procedures Removal
Report Audit Committee Report Audit Committee Board Directors
Report Board Directors Regarding Audit Matters Report Independent Registered Public Accounting Firm
Representations Warranties Covenants Investor Representations Warranties Investor
Required Vote Research Development
Research Development Expense Research Development Expenses
Research Development Expenses Accruals Research Licenses
Restatement Earnings Per Share Restricted Cash
Restricted Stock Award Restricted Stock Awards
Results Operations Financial Condition Results Presented Eortc-nci-aacr Cancer Symposium
Results Provides Corporate Update Revenue Recognition
Revocability Proxies Rights Agreement
Risks Related Business Risks Related Common Stock
Risks Related Intellectual Property Risks Related Ownership Common Stock
Royalties Royalty Payments Reports
Safe Harbor Safe Harbor Statement
Salaries Sales Milestone Payments
Schedule Scientific Clinical Advisory Board
Securities Exchange Act 1934 Securities Laws
Securities Registered Pursuant Act Securities Subject 2004 Plan
Securities Subject Amended Restated 2004 Equity Incentive Award Selling General Administrative Expense
Selling Restrictions Severance Agreement Rohan Palekar
Severance Benefits Severance Benefits Agreement
Severance Change Control Benefits Sfas 123
Sfas 151 Sfas 152
Sfas 153 Shares Stock
Shares Subject Plan Short-term Investments
Signature Signature Block Corporation Partnership Trust Other Entity
Signature Page Follows Signatures
Solicitation Sources Liquidity
Special Meetings Stock Appreciation Rights
Stock Based Compensation Stock Option Awards
Stock Options Stock Purchase Rights
Stock-based Compensation Stockholder Communications Board Directors
Stockholder Proposals Due Next Annual Meeting Stockholder Proposals Presented Next Annual Meeting Stockholders
Stockholder Recommendations Communication Board Directors Stockholder Record Shares Registered Name
Stockholders Meetings Stockholders Record Shares Registered Name
Strengthened Management Team Financial Position Study Design Results
Subgroup Analyses Sublicensing
Subscription Agreement Subsequent Event
Subsequent Events Subsidiaries Medivation Inc
Summary Compensation Table Switch Hormone-sensitive Castration-resistant State
Table Contents Tax Considerations
Taxes Team Expanded Anticipation Potential New Programs
Teleconference Webcast Teleconference Webcast Details
Tenure Duties Officers Termination
Termination Employment Terms Conditions Purchase Shares
Title Class Today 430 Eastern Time
Tony Vernon Joins Medivations Board Directors Trademarks Corporate Logos Other Intellectual Property Rights
Transactions Transactions Dara Biosciences Inc
Transactions Hung Transferees Thereof Shall Become Null Void Longer Transferable
Transfers Treatment Huntington Disease
Treatment Parachute Payments Underwritten Follow-on Offering
United States Updated 2009 Financial Outlook
Vacancies Vote
Vote Annual Meeting Votes
Votes Counted Votes Needed Approve Each Proposal
Voting Agreements Voting Rights Outstanding Shares
Warrants What Another Matter Properly Brought Before Meeting
What Broker Non-votes What Mean Receive Set Proxy Materials
What Proxy Materials Available Internet What Quorum Requirement
What Return Proxy Card Otherwise Vote Not Make What Voting
Xhibit Xhibit Ndex
Year-end 2008 Financial Results 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki